Tanvex BioPharmaTPE:6541 57 PS Ratio is 25.69 as of Jul. 13, 2026, which is 90% below its 10-year median of 254.79. GuruFocus rates TPE:6541 with a GF Score™ of 57/100 and a GF Value™ of NT$255.55 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, Tanvex BioPharma ranks worse than 70.32% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Tanvex BioPharma's share price is NT$40.80.
Tanvex BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.59. Hence, Tanvex BioPharma's PS Ratio for today is 25.69.
Good Sign:
Tanvex BioPharma Inc stock PS Ratio (=24.92) is close to 10-year low of 24.15.
The historical rank and industry rank for Tanvex BioPharma's PS Ratio or its related term are showing as below:
TPE:6541'
s PS Ratio Range Over the Past 10 Years
Min: 24.15 Med: 254.79 Max: 88072.48
Current: 25.69
During the past 13 years, Tanvex BioPharma's highest PS Ratio was 88072.48. The lowest was 24.15. And the median was 254.79.
TPE:6541's PS Ratio is ranked worse than 70.32% of 930
companies
in the Biotechnology industry
Industry Median: 9.49
vs TPE:6541: 25.69
During the past 12 months, the average Revenue per Share Growth Rate of Tanvex BioPharma was 634.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 106.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 188.20% per year.
During the past 13 years, Tanvex BioPharma's highest 3-Year average Revenue per Share Growth Rate was 440.20% per year. The lowest was 66.90% per year. And the median was 106.10% per year.
Back to Basics: PS Ratio
Tanvex BioPharma (TPE:6541) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Tanvex BioPharma PS Ratio Related Terms
Tanvex BioPharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Tanvex BioPharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tanvex BioPharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tanvex BioPharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Tanvex BioPharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Tanvex BioPharma's Share Price of today is NT$40.80. Tanvex BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.59.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Tanvex BioPharma (TPE:6541) has a PS Ratio of 25.69 as of Jul. 13, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Tanvex BioPharma and its competitors. This is 90% below median its historical median of 254.79. Over the past decade, Tanvex BioPharma's PS Ratio has ranged from 24.15 to 88,072.48. According to the industry distribution chart, Tanvex BioPharma ranks #654 out of 930 companies in the Biotechnology industry, placing it in the top 70.3%.
Is Tanvex BioPharma's PS Ratio too high?
Tanvex BioPharma's current PS Ratio of 25.69 is 90% below median its 10-year median of 254.79. Over the past 10 years, this metric has ranged from a low of 24.15 to a high of 88,072.48. The Biotechnology industry median PS Ratio is 9.49. Tanvex BioPharma's value of 25.69 is 170.7% above this industry median. Based on the distribution chart, Tanvex BioPharma ranks #654 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tanvex BioPharma ranks #654 out of 930 companies for PS Ratio. This places Tanvex BioPharma in the lower half of its industry. The industry median PS Ratio is 9.49. Tanvex BioPharma's value of 25.69 is 170.7% above this benchmark. Historically, Tanvex BioPharma's own PS Ratio has ranged from 24.15 to 88,072.48 over the past decade. While the company's 10-year median is 254.79 vs. the industry median of 9.49, Tanvex BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.49, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tanvex BioPharma's current PS Ratio of 25.69 is 170.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Tanvex BioPharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tanvex BioPharma's current PS Ratio is 25.69, which is 90% below median its own 10-year median of 254.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$255.55, compared to a current price of NT$40.80 — trading 84% below its estimated fair value. The current PS Ratio is 25.69, which is 90% below median its 10-year median of 254.79 and 170.7% above the Biotechnology industry median of 9.49. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current PS Ratio is 25.69 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?
Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued.
The current stock price of NT$40.80 is trading 84% below its estimated GF Value™ of NT$255.55.
GuruFocus considers Tanvex BioPharma to be Possible Value Trap.
Key valuation signals for TPE:6541:
PS Ratio: 25.69 (90% below median its 10-year median of 254.79)
GF Value™: NT$255.55 vs. price of NT$40.80 (84% below fair value)
Industry Position: 170.7% above the Biotechnology median (#654 of 930)
No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score
Get the complete analysis for TPE:6541
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6541 has been successfully added to your 
